IVIG Brands Comparison: A Patient’s Guide to Choosing the Right Product

Not all IVIG products are identical. While every FDA-approved brand contains purified human immunoglobulin G (IgG), they differ in stabilizers, IgA content, sugar content, sodium levels, osmolality, approved indications, and recommended infusion rates—differences that can directly affect how patients tolerate treatment and which brand their insurance will cover.

Why Your IVIG Brand Matters

When patients hear they need IVIG, the natural focus is on the condition being treated and the logistics of infusion. Few people think to ask, “Which brand will I be getting?” But the specific product matters more than most patients realize.

All IVIG brands share the same fundamental ingredient: concentrated IgG antibodies derived from pooled human plasma. Each manufacturer collects plasma from thousands of screened donors, then uses proprietary purification processes to isolate the IgG. It is in those manufacturing differences—how the product is purified, what stabilizers are added, and what gets removed—that meaningful clinical differences emerge.

Some patients tolerate one brand beautifully and experience significant IVIG side effects with another. This is not unusual, and it is not “in your head.” Differences in sugar content, sodium concentration, osmolality, and trace IgA levels all influence tolerability. Understanding these factors puts you in a stronger position to work with your healthcare team if problems arise.

The Major IVIG Brands

Privigen (CSL Behring)

Privigen is a 10% liquid formulation stabilized with L-proline, an amino acid. It contains no sugar, making it a preferred option for patients with diabetes or those at risk for renal complications associated with sucrose-containing products. Privigen has one of the higher IgA contents among IVIG brands, which is an important consideration for patients with IgA deficiency. It is FDA-approved for primary immunodeficiency (PIDD) and chronic immune thrombocytopenic purpura (ITP).

Gamunex-C (Grifols)

Gamunex-C is a 10% liquid formulation stabilized with glycine. It is sugar-free, sodium-free, and has a relatively low IgA content, making it a versatile option for many patients. Gamunex-C holds FDA approvals for PIDD, ITP, and chronic inflammatory demyelinating polyneuropathy (CIDP), giving it one of the broadest indication profiles among IVIG products. It can also be administered subcutaneously for PIDD.

Gammagard Liquid (Takeda)

Gammagard Liquid is a 10% formulation stabilized with glycine. It is notable for its very low IgA content—among the lowest of any IVIG brand—which makes it a consideration for patients with known IgA deficiency. It is approved for PIDD and multifocal motor neuropathy (MMN), and like Gamunex-C, it can be given subcutaneously. Takeda also manufactures Gammagard S/D, a lyophilized (freeze-dried) product with an even lower IgA content, though it requires reconstitution before use.

Octagam (Octapharma)

Octagam is available in both 5% and 10% concentrations. The 5% formulation is stabilized with maltose and is approved for PIDD. The 10% formulation uses maltose as well and is approved for ITP. Patients with diabetes should be aware that maltose can interfere with certain blood glucose monitoring systems, causing falsely elevated readings. As the FDA notes, only glucose-specific monitors should be used during and shortly after Octagam infusions.

Panzyga (Pfizer / Octapharma-origin)

Panzyga is a 10% liquid formulation stabilized with glycine. It is sugar-free and has a relatively low IgA content. Panzyga is FDA-approved for PIDD and ITP. It allows for a relatively fast maximum infusion rate compared to some other brands, which may translate to shorter infusion times for patients who tolerate it well.

Bivigam (ADMA Biologics)

Bivigam is a 10% liquid formulation stabilized with glycine. It is sugar-free and approved for PIDD. Bivigam was designed with a manufacturing process aimed at achieving consistent IgG subclass distribution, meaning the proportions of IgG1, IgG2, IgG3, and IgG4 closely mirror those found in normal human plasma.

Comprehensive Comparison Table

The following table summarizes the key formulation and clinical differences among the major IVIG brands available in the United States. These specifications come from each product’s FDA-approved prescribing information.

Key Differences That Affect Patients

IgA Content: Critical for IgA-Deficient Patients

IgA content varies substantially across brands. For most patients, this difference is clinically irrelevant. However, for the small percentage of patients who have complete IgA deficiency and have developed anti-IgA antibodies, even trace amounts of IgA can trigger serious allergic reactions, including anaphylaxis. If IgA deficiency has been identified, the prescribing physician will typically select a brand with the lowest available IgA content. Johns Hopkins Medicine provides more detail on IgA deficiency.

Sugar and Stabilizer Content: Kidney and Diabetes Considerations

The Mayo Clinic notes that sucrose-containing IVIG products carry a higher risk of kidney injury. While none of the major current brands use sucrose, Octagam’s maltose stabilizer deserves attention for patients who use blood glucose monitors. Maltose can cause falsely elevated glucose readings on monitors that use glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) test strips. Patients with diabetes should confirm their monitor uses a glucose-specific method.

Osmolality: Comfort and Tolerability

Osmolality measures how concentrated a solution is. Products with osmolality closer to that of blood (approximately 285 mOsm/kg) tend to be better tolerated and cause less discomfort at the infusion site. Gamunex-C and Gammagard Liquid have osmolality ranges closest to physiological levels, which may contribute to their tolerability profiles.

FDA Indications: Not Interchangeable for Every Condition

While doctors can prescribe any IVIG brand off-label, insurance companies often require that the specific product be FDA-approved for the patient’s diagnosis. For example, only Gamunex-C is currently approved for CIDP, and only Gammagard Liquid is approved for MMN. This can significantly limit choices for patients with these conditions.

Switching IVIG Brands

Brand switching happens more often than patients expect. Insurance formulary changes, supply shortages, and tolerability issues are the most common reasons. But switching is not always seamless.

What patients often learn the hard way: even though all brands contain IgG, your body may respond differently to a new product. Side effects that were well-controlled with one brand may resurface with another. This is not a sign that the new product is “worse”—it simply means the formulation difference is affecting you.

A practical tip that is rarely mentioned in prescribing guides: if you are forced to switch brands due to insurance, ask your pharmacist to document any adverse reactions you experience. This documentation can be valuable if you need to file an appeal to return to your original brand. Many insurance companies will approve a non-formulary brand if there is documented evidence of intolerance to the preferred product.

Insurance and Brand Selection

In an ideal world, the choice of IVIG brand would be a purely medical decision. In reality, insurance often plays a decisive role. Most insurance plans, including Medicare and Medicaid, have preferred product lists (formularies) that favor certain IVIG brands over others, usually based on negotiated pricing rather than clinical superiority.

Understanding IVIG insurance coverage is essential. Here is how the process typically works:

1. The prescribing physician orders IVIG for a specific diagnosis.
2. The specialty pharmacy contacts the insurer for prior authorization.
3. The insurer may approve the requested brand or require a “step therapy”—meaning the patient must try their preferred (cheaper) brand first.
4. If the patient experiences documented adverse effects with the insurer’s preferred brand, an appeal can be filed for the originally prescribed product.

When SCIg Might Be the Better Choice

For patients who struggle with tolerability across multiple IVIG brands, subcutaneous immunoglobulin (SCIg) may be worth discussing. SCIg delivers smaller, more frequent doses and generally produces fewer systemic side effects like headache and fatigue. The trade-off is more frequent administration (typically weekly) and potential local site reactions.

Currently available SCIg products in the United States include Hizentra (CSL Behring), Cuvitru (Takeda), Cutaquig (Octapharma), Xembify (Grifols), and the facilitated SCIg product Hyqvia (Takeda). Each has its own formulation characteristics, much like the IVIG brands discussed above.

Questions to Ask Your Doctor

Informed patients get better care. Before starting or switching IVIG, consider asking:

• Which IVIG brand are you prescribing, and why this one specifically?
• Does my insurance plan have a preferred IVIG brand, and is the prescribed brand on their formulary?
• Do I have any risk factors (IgA deficiency, kidney issues, diabetes) that should influence brand selection?
• What is the maximum infusion rate for this product, and how does it compare to what I have been receiving?
• If I have side effects with this brand, what is the process for trying a different one?
• Has there been any recent supply disruption for this brand that could affect my treatment schedule?

Supply shortages are a reality in the IVIG market. Plasma-derived products depend on a complex supply chain starting with human donors. Periodic shortages can force brand switches with little notice. Knowing your prescriber’s backup plan gives peace of mind.